The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED		IES AND EXCHANG	E COMMISSION	OMB APPROVAL
	Washi	ington, D.C. 20549 FORM D		OMB Number: 3235-0076
				Estimated average burden
	Notice of Exem	pt Offering of Secu	rities	hours per response: 4.00
1. Issuer's Identity				
CIK (Filer ID Number)	Previous Names	None	Entity Type	
0001420720	iBioPharma,	Inc.	X Corporation	
Name of Issuer	InB:Biotechn	ologies, Inc.	Limited Partnersh	nip
iBio, Inc.			Limited Liability C	
Jurisdiction of Incorporation/Organization				
DELAWARE			General Partners	nip
Year of Incorporation/Organization			Business Trust	
X Over Five Years Ago			Other (Specify)	
Within Last Five Years (Specify Year)				
Yet to Be Formed				
2. Principal Place of Business and Con	tact Information			
Name of Issuer				
iBio, Inc.				
Street Address 1		Street Address 2		
11750 SORRENTO VALLEY ROAD, SUIT				
	e/Province/Country	ZIP/PostalCode	Phone Number of I	ssuer
SAN DIEGO CALI	IFORNIA	92121	(979) 446-0027	
3. Related Persons				
Last Name	First Name		Middle Name	
Brenner	Martin		А.	
Street Address 1	Street Address 2			
11750 Sorrento Valley Road, Suite 200				
City	State/Province/Co	ountry	ZIP/PostalCode	
San Diego	CALIFORNIA		92121	
Relationship: X Executive Officer X Direct	ctor Promoter			
Clarification of Response (if Necessary):				
Last Name	First Name		Middle Name	
Duran	Felipe			
Street Address 1	Street Address 2			
11750 Sorrento Valley Road, Suite 200				
City	State/Province/Co	buntry	ZIP/PostalCode	
San Diego	CALIFORNIA		92121	
Relationship: X Executive Officer Direct	ctor Promoter			
Clarification of Response (if Necessary):				
Last Name	First Name		Middle Name	
Shimmelpennink	Evert			
Street Address 1	Street Address 2			
11750 Sorrento Valley Road, Suite 200				
City	State/Province/Co	buntry	ZIP/PostalCode	
San Diego	CALIFORNIA		92121	
Relationship: Executive Officer X Direct	ctor Promoter			

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Kroptova	Alexandra	
Street Address 1	Street Address 2	
11750 Sorrento Valley Road, Suite 200		
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92121
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Clark	William	
Street Address 1	Street Address 2	
11750 Sorrento Valley Road, Suite 200		
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92121
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Sender	Gary	
Street Address 1	Street Address 2	
11750 Sorrento Valley Road, Suite 200		
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92121
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Arkowitz	David	
Street Address 1	Street Address 2	
11750 Sorrento Valley Road, Suite 200		
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92121
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Parada	Antonio	
Street Address 1	Street Address 2	
11750 Sorrento Valley Road, Suite 200		
City	State/Province/Country	ZIP/PostalCode
San Diego Relationship: Executive Officer X Director	CALIFORNIA	92121
Clarification of Response (if Necessary):	rionolei	
Last Name	First Name	Middle Name
Banjak	Marc	
Street Address 1	Street Address 2	
11750 Sorrento Valley Road, Suite 200	State / Dwo vines / Country	
City See Diese	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92121
Relationship: X Executive Officer Director	Promoter	
Clarification of Response (if Necessary):		
4. Industry Group		

Agriculture	Health Care	Retailing
Banking & Financial Services	X Biotechnology	 ∏ Restaurants
Commercial Banking	Health Insurance	
		Technology
		Computers
	Hospitals & Physicians	Telecommunications
Investment Banking	Pharmaceuticals	
Pooled Investment Fund		Other Technology
Is the issuer registered as	Other Health Care	Travel
an investment company under	Manufacturing	Airlines & Airports
the Investment Company Act of 1940?	Real Estate	
Yes No	Commercial	Lodging & Conventions
		Tourism & Travel Services
Other Banking & Financial Services	Construction	Other Travel
Business Services	REITS & Finance	
Energy	Residential	Other
Coal Mining		
	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		

### 5. Issuer Size

Oil & Gas

Other Energy

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

## 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)	
	Section 3(c)(1)	Section 3(c)(9)
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(i)		
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)
Rule 506(b)	Section 3(c)(5)	Section 3(c)(13)
Rule 506(c)		
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)
	Section 3(c)(7)	

## 7. Type of Filing

X

Amendment

8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	25 X No	
9. Type(s) of Securities Offered (select all that apply)		
Equity     Debt     Option, Warrant or Other Right to Acquire Another Security     Security to be Acquired Upon Exercise of Option, Warrant or Other F     Acquire Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Right to Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combination t or exchange offer?	transaction, such as a merger, acquisition $\Box$ Yes X No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 USD		
12. Sales Compensation		
Recipient Chardan Capital Markets LLC	Recipient CRD Number None	
(Associated) Broker or Dealer X None None Street Address 1 17 State Street, Suite 2130	(Associated) Broker or Dealer CRD Number X None None Street Address 2	
City New York State(s) of Solicitation (select all that apply)	State/Province/Country NEW YORK	ZIP/Postal Code 10020
Check "All States" or check individual States          GEORGIA         MASSACHUSETTS         NEW YORK         TEXAS         PUERTO RICO		
13. Offering and Sales Amounts		
Total Offering Amount\$11,084,569 USD orIndefiniteTotal Amount Sold\$11,084,569 USDTotal Remaining to be Sold\$0 USD orIndefinite		
Clarification of Response (if Necessary):		
Includes \$0.125 per share received upon sale of warrants and \$0.86 per share the	hat may be received upon future exercise of warrants	
14. Investors		
Select if securities in the offering have been or may be sold to personance such non-accredited investors who already have invested in the offer Regardless of whether securities in the offering have been or may be total number of investors who already have invested in the offering:	ering. be sold to persons who do not qualify as accredited investors	
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders fees check the box next to the amount.	expenses, if any. If the amount of an expenditure is not know	n, provide an estimate and
Sales Commissions \$217,000 USD X Estimate		
Finders' Fees \$0 USD Estimate		

#### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD X Estimate

Clarification of Response (if Necessary):

While no offering proceeds are set aside for payments to named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.

#### Signature and Submission

## Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
iBio, Inc.	/s/ Marc Banjak	Marc Banjak	Chief Legal Officer	2025-05-07

# Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials only to the extent NSMIA permits them to do so under NSMIA's NSMIA's porterior to the interview of the observation of their anti-fraud authority.